These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20403033)

  • 1. Comparison of immunohistochemistry assays and real-time reverse transcription-polymerase chain reaction for analyzing hormone receptor status in human breast carcinoma.
    Oda M; Arihiro K; Kataoka T; Osaki A; Asahara T; Ohdan H
    Pathol Int; 2010 Apr; 60(4):305-15. PubMed ID: 20403033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
    Badve SS; Baehner FL; Gray RP; Childs BH; Maddala T; Liu ML; Rowley SC; Shak S; Perez EA; Shulman LJ; Martino S; Davidson NE; Sledge GW; Goldstein LJ; Sparano JA
    J Clin Oncol; 2008 May; 26(15):2473-81. PubMed ID: 18487567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay.
    Chae BJ; Bae JS; Yim HW; Lee A; Song BJ; Jeon HM; Chun MH; Jung SS
    Pathology; 2011 Apr; 43(3):248-53. PubMed ID: 21436635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
    Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
    Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor alpha and beta profiling in human breast cancer.
    Balfe P; McCann A; McGoldrick A; McAllister K; Kennedy M; Dervan P; Kerin MJ
    Eur J Surg Oncol; 2004 Jun; 30(5):469-74. PubMed ID: 15135471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of current prognostic and predictive markers in breast cancer: a validation study of tissue microarrays.
    Batistatou A; Televantou D; Bobos M; Eleftheraki AG; Kouvaras E; Chrisafi S; Koukoulis GK; Malamou-Mitsi V; Fountzilas G
    Anticancer Res; 2013 May; 33(5):2139-45. PubMed ID: 23645767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of a repressor of estrogen receptor activity in human breast tumors: relationship to some known prognostic markers.
    Simon SL; Parkes A; Leygue E; Dotzlaw H; Snell L; Troup S; Adeyinka A; Watson PH; Murphy LC
    Cancer Res; 2000 Jun; 60(11):2796-9. PubMed ID: 10850416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
    Sughayer MA; Alhassoon S; Sughayer HM
    Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
    Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
    Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
    He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
    Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki-67 expression in operable breast cancer: a comparative study of immunostaining and a real-time RT-PCR assay.
    Potemski P; Pluciennik E; Bednarek AK; Kusinska R; Kubiak R; Jesionek-Kupnicka D; Watala C; Kordek R
    Pathol Res Pract; 2006; 202(7):491-5. PubMed ID: 16678980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of estrogen receptor variant messenger RNAs and determination of estrogen receptor status in human breast cancer.
    Huang A; Leygue ER; Snell L; Murphy LC; Watson PH
    Am J Pathol; 1997 May; 150(5):1827-33. PubMed ID: 9137105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
    Oyaizu T; Arita S; Hatano T; Tsubura A
    J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.